Anti-tumor necrosis factor therapy in patients with inflammatory bowel disease; comorbidity, not patient age, is a predictor of severe adverse events - Asscher, V ER; van der Vliet, Q; van der Aalst, K (Int J Colorectal Dis, 2020)
et al.